The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Regent Laporte - One of the best experts on this subject based on the ideXlab platform.
-
unlike arginine vasopressin the selective v1a Receptor Agonist fe 202158 does not cause procoagulant effects by releasing von willebrand factor
Critical Care Medicine, 2012Co-Authors: Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg, Nicky Ferdyan, Kazimierz Wisniewski, L D Traber, Claudio D Schteingart, Pierre Riviere, Regent LaporteAbstract:Objective:To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 Receptor Agonist arginine vasopressin and the selective vasopressin type 1a Receptor Agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic s
-
selective v1a Receptor Agonist fe 202158 reverses platelet activating factor induced hypotension vascular leak impaired tissue perfusion and mortality in rats
Critical Care, 2008Co-Authors: Regent Laporte, James A Russell, Donald W Landry, Pierre J M RiviereAbstract:Platelet-activating factor (PAF) is a phospholipid autacoid inducing peripheral vasodilation and vascular leak, both pathophysiological hallmarks of sepsis-induced cardiovascular dysfunction resulting in hypotension [1]. Indeed, PAF has been implicated in various animal models of sepsis and in septic humans [2]. A deficiency in the vasopressor hormone arginine vasopressin (AVP), a mixed V1a/V2 Receptor Agonist, also contributes to the cardiovascular dysfunction of septic shock, leading to clinical use of AVP for this condition [3,4]. These various findings led us to hypothesize that the selective V1a Receptor Agonist FE 202158 would be effective in a rat model of PAF-induced hypotension.
Kazimierz Wisniewski - One of the best experts on this subject based on the ideXlab platform.
-
pharmacological characterization of fe 201874 the first selective high affinity rat v1a vasopressin Receptor Agonist
British Journal of Pharmacology, 2013Co-Authors: Rafik Marir, Kazimierz Wisniewski, Anne Virsolvy, Julie Mion, Dominique Haddou, Evelyne Galibert, Zahia MeraihiAbstract:BACKGROUND AND PURPOSE Distinct vasopressin Receptors are involved in different physiological and behavioural functions. Presently, no selective Agonist is available to specifically elucidate the functional roles of the V1A Receptor in the rat, one of the most widely used animal models. FE 201874 is a new derivative of the human selective V1A Receptor Agonist F180. In this study, we performed a multi-approach pharmacological and functional characterization of FE 201874 to determine whether it is selective for V1A Receptors.
-
unlike arginine vasopressin the selective v1a Receptor Agonist fe 202158 does not cause procoagulant effects by releasing von willebrand factor
Critical Care Medicine, 2012Co-Authors: Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg, Nicky Ferdyan, Kazimierz Wisniewski, L D Traber, Claudio D Schteingart, Pierre Riviere, Regent LaporteAbstract:Objective:To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 Receptor Agonist arginine vasopressin and the selective vasopressin type 1a Receptor Agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic s
Sebastian Rehberg - One of the best experts on this subject based on the ideXlab platform.
-
unlike arginine vasopressin the selective v1a Receptor Agonist fe 202158 does not cause procoagulant effects by releasing von willebrand factor
Critical Care Medicine, 2012Co-Authors: Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg, Nicky Ferdyan, Kazimierz Wisniewski, L D Traber, Claudio D Schteingart, Pierre Riviere, Regent LaporteAbstract:Objective:To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 Receptor Agonist arginine vasopressin and the selective vasopressin type 1a Receptor Agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic s
Pierre J M Riviere - One of the best experts on this subject based on the ideXlab platform.
-
selective v1a Receptor Agonist fe 202158 reverses platelet activating factor induced hypotension vascular leak impaired tissue perfusion and mortality in rats
Critical Care, 2008Co-Authors: Regent Laporte, James A Russell, Donald W Landry, Pierre J M RiviereAbstract:Platelet-activating factor (PAF) is a phospholipid autacoid inducing peripheral vasodilation and vascular leak, both pathophysiological hallmarks of sepsis-induced cardiovascular dysfunction resulting in hypotension [1]. Indeed, PAF has been implicated in various animal models of sepsis and in septic humans [2]. A deficiency in the vasopressor hormone arginine vasopressin (AVP), a mixed V1a/V2 Receptor Agonist, also contributes to the cardiovascular dysfunction of septic shock, leading to clinical use of AVP for this condition [3,4]. These various findings led us to hypothesize that the selective V1a Receptor Agonist FE 202158 would be effective in a rat model of PAF-induced hypotension.
Zahia Meraihi - One of the best experts on this subject based on the ideXlab platform.
-
pharmacological characterization of fe 201874 the first selective high affinity rat v1a vasopressin Receptor Agonist
British Journal of Pharmacology, 2013Co-Authors: Rafik Marir, Kazimierz Wisniewski, Anne Virsolvy, Julie Mion, Dominique Haddou, Evelyne Galibert, Zahia MeraihiAbstract:BACKGROUND AND PURPOSE Distinct vasopressin Receptors are involved in different physiological and behavioural functions. Presently, no selective Agonist is available to specifically elucidate the functional roles of the V1A Receptor in the rat, one of the most widely used animal models. FE 201874 is a new derivative of the human selective V1A Receptor Agonist F180. In this study, we performed a multi-approach pharmacological and functional characterization of FE 201874 to determine whether it is selective for V1A Receptors.
